Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The 25 kDa ookinete surface antigen (Pfs25) is a sexual-stage surface protein of the malaria parasite Plasmodium falciparum. It is expressed predominantly on the surface of zygotes and ookinetes within the midgut of the female Anopheles mosquito vector after fertilization. Structurally, Pfs25 is a glycosylphosphatidylinositol (GPI)-anchored protein containing four tandem epidermal growth factor (EGF)-like domains rich in disulfide bonds. Because Pfs25 is not expressed during the asexual blood stages in the human host, it is not exposed to natural immune selection pressure, making it highly conserved among diverse parasite isolates. This conservation makes Pfs25 a leading candidate for the development of malaria transmission-blocking vaccines (TBVs).
Vaccines targeting Pfs25, such as Pfs25-EPA and Pfs25-IMX313, aim to elicit high titers of functional antibodies in the human host. When a mosquito feeds on a vaccinated individual, it ingests these antibodies along with gametocytes. Within the mosquito midgut, the antibodies bind to Pfs25 on the surface of the developing zygotes and ookinetes, preventing their traversal of the midgut epithelium and subsequent development into oocysts, thereby breaking the cycle of malaria transmission. Passive administration of transmission-blocking monoclonal antibodies (such as 4B7) is also being explored. Major challenges in targeting Pfs25 include its poor immunogenicity as a monomeric protein, which necessitates conjugation to carrier proteins (like ExoProtein A) or presentation on virus-like particles, and the rapid decay of antibody titers, which requires potent adjuvants that can sometimes cause systemic reactogenicity.
Elicitation of transmission-blocking antibodies that bind to the parasite surface in the mosquito midgut, preventing ookinete development and oocyst maturation
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 25 kDa ookinete surface antigen (Pfs25) (Pfs25).